Hypera S.a. · BMFBOVESPA:HYPE3
Hypera — Q2 2022 Earnings Presentation
9 slides from Hypera's earnings presentation, Jul 29, 2022
Slide 1: 2Q22 Earnings Presentation
2Q22 Earnings Presentation July 29, 2022
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: Quarterly period timeline 4Q20 to 2Q22
4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3
Slide 4: 2022 Launches
2022 Launches neo ~ uimica ss Quimica ManteeorD Mantecorp saneare pielus NOUVE DA |e | oct | _— e666 6 66 E OOOOOOX | For I SH ypera
Slide 5: Institutional Market
Institutional Market Interest on Equity approval of R$194.8 million (R$0.31/share) 2021 Annual Report
Slide 6: 2Q22 Results (R$ million)
2Q22 Results (RS million) NET REVENUE > R$1,895.6 +25.8% GROSS MARGIN 63.7%? -180bps' MARKETING EXPENSES 16.5%? -330bps! SELLING EXPENSES 10.0%? -10bps! GENERAL AND ADMINISTRATIVE EXPENSES 3.7%? -20bps! EBITDA MARGIN FROM CONTINUING OP. (excl. OTHERS) 35.6%? +150bps! NET INCOME FROM CONTINUING OPERA
Slide 7: Cash flow and net debt bridge 1Q22 to 2Q22
1Q22 Gross Cash Flow from CAPEX Intangibles Free Cash Flow Cash Flow from IOC 2Q22 Gross 2Q22 Gross 2Q22 Net Debt Cash Operations 2Q22 Financing Cash Debt
Slide 8: Sell-out Pharmaceutical Retail
Sell-out1 Pharmaceutical Retail (Sell-Out PPP YTD) #1
Slide 9: Slide 9
Hypera — Q2 2022 Earnings Presentation on 6ix